RESOURCES
How teams can use technology to address issues of diversity across the drug and device development lifecycle.
Prior to 2020, many clinical teams approached virtual engagement with an experimental mindset. But when COVID-19 derailed trials and changed how global teams worked together, clinical groups quickly learned the benefits of combining asynchronous virtual engagement with live touchpoints. In this white paper, clinical team leads will learn how their peers are using hybrid virtual engagement to get more actionable insights, prioritize patient-centricity, gather more diverse perspectives, and overcome budget limitations.
The new, tech-enabled approach to congress planning adds value to medical conference attendance – before, during, and after the event.
How life science teams can achieve their targets through improved digital opinion leader selection.
